KTT2: Renin-angiotensin system drugs
... infarction, chronic kidney disease and type 1 and type 2 diabetes. Treatment of these conditions is complex, and there are multiple indications for each drug. The decision to prescribe an ACE inhibitor or an ARB, and whether an ACE inhibitor plus an ARB would be beneficial, should be made with each ...
... infarction, chronic kidney disease and type 1 and type 2 diabetes. Treatment of these conditions is complex, and there are multiple indications for each drug. The decision to prescribe an ACE inhibitor or an ARB, and whether an ACE inhibitor plus an ARB would be beneficial, should be made with each ...
Management of Drug Formulary
... -provides for a high level of flexibility -most of the time utilizes 3-tier benefit design, but can more ...
... -provides for a high level of flexibility -most of the time utilizes 3-tier benefit design, but can more ...
Shared Care Guidelines available. For the treatment
... Responsibilities of the specialist initiating treatment 1. Initiate and stabilise treatment with quetiapine (this phase is expected to last at least six months). To initiate therapy, arrange prescription and evaluate over the first 3 months. To establish baseline and after 3 months of treatment weig ...
... Responsibilities of the specialist initiating treatment 1. Initiate and stabilise treatment with quetiapine (this phase is expected to last at least six months). To initiate therapy, arrange prescription and evaluate over the first 3 months. To establish baseline and after 3 months of treatment weig ...
Barnsley Area Prescribing Committee
... careful clinical monitoring should be followed closely, especially at initiation of lixisenatide treatment. If such medicinal products are to be administered with food, patients should be advised to, if possible, take them with a meal when lixisenatide is not administered. For oral medicinal product ...
... careful clinical monitoring should be followed closely, especially at initiation of lixisenatide treatment. If such medicinal products are to be administered with food, patients should be advised to, if possible, take them with a meal when lixisenatide is not administered. For oral medicinal product ...
Opiate Detox Guidelines
... Criteria for community detoxification using Lofexidine: Completed a NHS Borders Addiction Service assessment that includes; mental health assessment, physical health assessment, drug use history and life/ social history. Confirmed as opiate dependent and must not be prescribed or taking illicit benz ...
... Criteria for community detoxification using Lofexidine: Completed a NHS Borders Addiction Service assessment that includes; mental health assessment, physical health assessment, drug use history and life/ social history. Confirmed as opiate dependent and must not be prescribed or taking illicit benz ...
PROF. Rosita Aniuliene LITHUANIAN UNIVERSITY OF HEALTH
... nervous stimulation and cystoplasty are not appropriate ...
... nervous stimulation and cystoplasty are not appropriate ...
Additional Service – Needle Exchange
... which will be met by the PCT. Contractors will share relevant information with other health care professionals and agencies, in line with locally determined confidentiality arrangements. The Contractor needle and syringe exchange service is part of a wider exchange scheme coordinated by the local sp ...
... which will be met by the PCT. Contractors will share relevant information with other health care professionals and agencies, in line with locally determined confidentiality arrangements. The Contractor needle and syringe exchange service is part of a wider exchange scheme coordinated by the local sp ...
Methylphenidate - Isle of Wight NHS Trust
... monitoring for reports of ADR`s from the patient, carer, GP or any individual of the MDT involved in that patients management. The Community Psychiatrist will liaise with the GP and share the patients care once a stable, optimum dose has been achieved. It is accepted that until an effective acceptab ...
... monitoring for reports of ADR`s from the patient, carer, GP or any individual of the MDT involved in that patients management. The Community Psychiatrist will liaise with the GP and share the patients care once a stable, optimum dose has been achieved. It is accepted that until an effective acceptab ...
Leishmaniasis Factsheet
... is developing a topical treatment based on amphotericin B. In the longer term, DNDi aims to develop a novel field-adapted modality of treatment for CL caused by L. tropica and L. braziliensis that would combine anti-parasite and immune-modifying agents, with a strong emphasis on safety, efficacy, co ...
... is developing a topical treatment based on amphotericin B. In the longer term, DNDi aims to develop a novel field-adapted modality of treatment for CL caused by L. tropica and L. braziliensis that would combine anti-parasite and immune-modifying agents, with a strong emphasis on safety, efficacy, co ...
STOPP START Toolkit Supporting Medication Review
... rationale for the intervention is given in italics. The process of medication review is covered in the practice guide to clinical medication review.5 As well as using the list of drugs here to decide which might need to be stopped in the frail elderly it should also be considered if the drug gives d ...
... rationale for the intervention is given in italics. The process of medication review is covered in the practice guide to clinical medication review.5 As well as using the list of drugs here to decide which might need to be stopped in the frail elderly it should also be considered if the drug gives d ...
Painful Peripheral Neuropathy
... Referral into the Specialist Diabetes Foot Care Service can be made at any point but would typically be recommended if Amitriptyline and / or topical therapies had been unsuccessful. The following services are available to patients: Painful Peripheral Diabetic Neuropathy Education Groups – These are ...
... Referral into the Specialist Diabetes Foot Care Service can be made at any point but would typically be recommended if Amitriptyline and / or topical therapies had been unsuccessful. The following services are available to patients: Painful Peripheral Diabetic Neuropathy Education Groups – These are ...
Document name: ANTIDEPRESSANTS FOR THE TREATMENT OF
... ulcers. The risk of gastric bleeding is increased when aspirin, clopidogrel or NSAIDS are co-prescribed. The elderly and those with a previous history of bleeding are at greatest risk. Gastroprotective drugs such as omeprazole or lansoprazole should be considered in patients taking SSRIs with risk f ...
... ulcers. The risk of gastric bleeding is increased when aspirin, clopidogrel or NSAIDS are co-prescribed. The elderly and those with a previous history of bleeding are at greatest risk. Gastroprotective drugs such as omeprazole or lansoprazole should be considered in patients taking SSRIs with risk f ...
Rational use of anti-tuberculosis drugs in the EU: better EDITORIAL
... TB drug discovery pipeline appears promising; however, there are only two new classes of drugs, which are currently undergoing final phases of clinical trials and may be widely available in the next 2 yrs [19, 21, 22]. Recently, concerns have been raised about whether the use of new TB drugs should ...
... TB drug discovery pipeline appears promising; however, there are only two new classes of drugs, which are currently undergoing final phases of clinical trials and may be widely available in the next 2 yrs [19, 21, 22]. Recently, concerns have been raised about whether the use of new TB drugs should ...
New Drugs from Old
... Cardura XL • In the UK, licensed for hypertension & BPH • Claimed advantages are reduced risk of hypotension due to lower peak blood levels • Combined results of two double-blind RCTs (705 patients) suggest immediate release doxazosin is as effective with no significant difference in adverse effect ...
... Cardura XL • In the UK, licensed for hypertension & BPH • Claimed advantages are reduced risk of hypotension due to lower peak blood levels • Combined results of two double-blind RCTs (705 patients) suggest immediate release doxazosin is as effective with no significant difference in adverse effect ...
Drugs for Dementia
... They can be re-referred back to the appropriate memory service via the normal referral pathway. When to seek Specialist advice / review You can get advice regarding patients taking drug treatments for dementia from the locality memory treatment services in addition to CCG community pharmacy support ...
... They can be re-referred back to the appropriate memory service via the normal referral pathway. When to seek Specialist advice / review You can get advice regarding patients taking drug treatments for dementia from the locality memory treatment services in addition to CCG community pharmacy support ...
Presentation - Chronice Myeloid Leukemia
... NB: Can still get other drugs for certain patients via the Cancer Drugs Fund 1. NICE. Technology appraisal 251. 2. NICE. Technology appraisal 241. ...
... NB: Can still get other drugs for certain patients via the Cancer Drugs Fund 1. NICE. Technology appraisal 251. 2. NICE. Technology appraisal 241. ...
Pharmaceutical pricing in France: a critique
... These examples demonstrate that rebate schemes are necessary to limit price increases in France and to monitor drug use. However, their impact should not be overestimated. Prices are essential in any regulated market to send the right message. Many factors in the system may lead to spontaneous price ...
... These examples demonstrate that rebate schemes are necessary to limit price increases in France and to monitor drug use. However, their impact should not be overestimated. Prices are essential in any regulated market to send the right message. Many factors in the system may lead to spontaneous price ...
nhse_qa43_7_final - Specialist Pharmacy Service
... AED. This period should be increased to 8 weeks after more prolonged used of enzyme inducers. In all cases, the pill-free interval should be omitted when switching back to a standard or low-dose COC ...
... AED. This period should be increased to 8 weeks after more prolonged used of enzyme inducers. In all cases, the pill-free interval should be omitted when switching back to a standard or low-dose COC ...
Esomeprazole - Medicines Management in the East Lancashire
... strategy may diminish over time. NICE does not advocate the use of one PPI in preference to another. Previous systematic reviews suggest that there is no statistically significant difference between the different PPIs at equivalent doses. As such, the first line choices of PPIs in East Lancashire ar ...
... strategy may diminish over time. NICE does not advocate the use of one PPI in preference to another. Previous systematic reviews suggest that there is no statistically significant difference between the different PPIs at equivalent doses. As such, the first line choices of PPIs in East Lancashire ar ...
ISTRUZIONI PER PREPARARE POSTER DA ESPORRE A …
... Studies on the use of combined treatments in elderly patients with multiple diseases. NB: this research topic is aimed at studying patients affected by hypertension, diabetes, cardiovascular diseases, also in association with other clinical conditions. The application to these patients of available ...
... Studies on the use of combined treatments in elderly patients with multiple diseases. NB: this research topic is aimed at studying patients affected by hypertension, diabetes, cardiovascular diseases, also in association with other clinical conditions. The application to these patients of available ...
Pharmacy Medical Necessity Guidelines: Crestor
... coverage criteria based on current literature review, consultation with practicing physicians in the service area who are medical experts in the particular field, FDA and other government agency policies, and standards adopted by national accreditation organizations. The plan revises and updates Ph ...
... coverage criteria based on current literature review, consultation with practicing physicians in the service area who are medical experts in the particular field, FDA and other government agency policies, and standards adopted by national accreditation organizations. The plan revises and updates Ph ...
2. Template for full shared care Jan 2014
... The information in the shared care guideline has been developed in consultation with CCGs in South East London and it has been agreed that it is suitable for shared care. This document should provide sufficient information to enable you to make an informed decision regarding the clinical and legal r ...
... The information in the shared care guideline has been developed in consultation with CCGs in South East London and it has been agreed that it is suitable for shared care. This document should provide sufficient information to enable you to make an informed decision regarding the clinical and legal r ...
GP at 6 months in between specialist reviews
... Lisdexamfetamine is licensed for use as a second line agent to methylphenidate. This should preferably be done after the use of at least two modified release preparations of methylphenidate unless a previous adverse reaction to methylphenidate or unacceptable side effect has ruled out further use. I ...
... Lisdexamfetamine is licensed for use as a second line agent to methylphenidate. This should preferably be done after the use of at least two modified release preparations of methylphenidate unless a previous adverse reaction to methylphenidate or unacceptable side effect has ruled out further use. I ...
2014 Evidence-Based Guideline for the Management of High Blood
... drug or add a second drug from one of the classes in recommendation 6 (thiazidetype diuretic, CCB, ACEI, or ARB). The clinician should continue to assess BP and adjust the treatment regimen until goal BP is reached. If goal BP cannot be reached with 2 drugs, add and titrate a third drug from the lis ...
... drug or add a second drug from one of the classes in recommendation 6 (thiazidetype diuretic, CCB, ACEI, or ARB). The clinician should continue to assess BP and adjust the treatment regimen until goal BP is reached. If goal BP cannot be reached with 2 drugs, add and titrate a third drug from the lis ...
Dolutegravir for treatment of HIV
... commissioning of dolutegravir for specific patient groups. The objectives are to enable access to dolutegravir where its use is supported by clinical evidence and where it is demonstrated to represent good value. Dolutegravir is price comparative to second line therapies. This policy aims to identif ...
... commissioning of dolutegravir for specific patient groups. The objectives are to enable access to dolutegravir where its use is supported by clinical evidence and where it is demonstrated to represent good value. Dolutegravir is price comparative to second line therapies. This policy aims to identif ...